CoChat
Sign Up
Cited by 10

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice

Schlunk, Frieder, Fischer, Paul, Princen, Hans M.G., Rex, Andre, Prinz, Vincent, Foddis, Marco, Lütjohann, Dieter, Laufs, Ulrich, Endres, Matthias·2021·Behavioural Brain Research
DOI 10.1016/j.bbr.2020.112875
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbr.2020.112875

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 14

  1. Sabatine, 2015, Pcsk9 inhibitors and cardiovascular events, N Engl J Med, 373, 774
  2. Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 · DOI · Paper page
  3. Ason, 2014, Pcsk9 inhibition fails to alter hepatic ldlr, circulating cholesterol, and atherosclerosis in the absence of apoe, J Lipid Res, 55, 2370, 10.1194/jlr.M053207 · DOI
  4. Tanila, 2018, Testing cognitive functions in rodent disease models: Present pitfalls and future perspectives, Behav Brain Res, 352, 23, 10.1016/j.bbr.2017.05.040 · DOI
  5. Antunes, 2012, The novel object recognition memory: Neurobiology, test procedure, and its modifications, Cogn Process, 13, 93, 10.1007/s10339-011-0430-z · DOI · Paper page
  6. Winter, 2004, Dysexecutive syndrome after mild cerebral ischemia? Mice learn normally but have deficits in strategy switching, Stroke, 35, 191, 10.1161/01.STR.0000107188.29688.2C · DOI
  7. Winter, 2005, Anxious and hyperactive phenotype following brief ischemic episodes in mice, Biol Psychiatry, 57, 1166, 10.1016/j.biopsych.2005.02.010 · DOI
  8. Kronenberg, 2008, Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase, J Neurosci, 28, 7219, 10.1523/JNEUROSCI.0940-08.2008 · DOI
  9. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (narc-1): Liver regeneration and neuronal differentiation, Proc Natl Acad Sci U S A, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  10. McCormack, 2016, Very low ldl-c levels may safely provide additional clinical cardiovascular benefit: The evidence to date, Int J Clin Pract, 70, 886, 10.1111/ijcp.12881 · DOI · Paper page
  11. Koren, 2017, Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label osler-1 extension study, JAMA Cardiol, 2, 598, 10.1001/jamacardio.2017.0747 · DOI
  12. Harvey, 2018, No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: A meta-analysis of individual patient data, Eur Heart J., 39, 374, 10.1093/eurheartj/ehx661 · DOI
  13. van Vlijmen, 1996, Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein e3-leiden transgenic mice, J Clin Invest, 97, 1184, 10.1172/JCI118532 · DOI
  14. Schuster, 2019, Anti-pcsk9 antibodies inhibit pro-atherogenic mechanisms in apoe*3leiden.Cetp mice, Sci Rep., 9, 11079, 10.1038/s41598-019-47242-0 · DOI

Cited by

Sorted by citations

See all 10

Metadata

Authors
Schlunk, F., Fischer, P., Princen, H. M. G., Rex, A., Prinz, V., Foddis, M., Lütjohann, D., Laufs, U., & Endres, M.
ORCID
Venue
Behavioural Brain Research
Publisher
Elsevier BV
Published
2021-01
Volume
396
Pages
112875
ISSN
0166-4328
DOI
10.1016/j.bbr.2020.112875
Cited by
10
References
9
Language
en
Licence
Funders
Charité –Universitätsmedizin Berlin and the Berlin Institute of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review